Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sartorius Stedim Biotech    DIM   FR0013154002

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

SARTORIUS STED BIO : Sartorius Stedim Biotech and c-LEcta sign sales agreement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/03/2012 | 01:05pm CEST
SSB sells and distributes Serratia marcescens nuclease worldwide | Perfect addition to SSB´s purification product portfolio

Goettingen | Leipzig, Germany, May 3, 2012 - Sartorius Stedim Biotech, a leading international pharma and biotech supplier, and the biotechnology specialist c LEcta, announce the signing of a worldwide sales and distribution agreement for c LEcta's proprietary Serratia marcescens nuclease for biopharmaceutical applications. The German company specializes in the development of customized enzymes and production strains for industrial applications. Based on this agreement, customized endonuclease will now be available under the product name "Denarase" through all regular Sartorius Stedim Biotech sales channels.

Endonucleases are used in various biopharmaceutical production processes, such as in recombinant protein production, to remove nucleic acids, reduce viscosity levels and thus optimize process efficiencies. The company c-LEcta has optimized the production process for Serratia marcescens nuclease using a genetically engineered Bacillus strain to increase enzyme activity yields and remove endotoxins. As a result, this new technology enables the highest purity and quality nuclease to be produced.

"This endonuclease provides outstanding advantages from which our customers will benefit directly, such as cost efficiency and high performance," says Dr. Uwe Gottschalk, Vice President of Purification Technologies at Sartorius Stedim Biotech. "The nuclease is a perfect addition to our current purification product portfolio and supports our strategy as a total solution provider for the biopharmaceutical industry."

Dr. Marc Struhalla, Managing Director of c-LEcta comments, "The technology developed by c-LEcta allows us to provide nuclease to our customers in the highest quality. We are convinced that with Sartorius Stedim Biotech, we have found the right sales and distribution partner for the successful worldwide commercialization of our product."

About c-LEcta GmbH

c-LEcta is a German biotechnology company specializing in the development of customized enzymes and production strains for industrial applications. Patented technologies are employed for discovery and optimization of tailor-made enzymes and microbial strains. c-LEcta's know-how in microbiology and strain engineering allows efficient development of production strains for protein and small-molecule products. Proprietary technologies are used for the identification of new enzymes from biodiversity and for effective enzyme engineering.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SARTORIUS STEDIM BIOTECH
07/21 SARTORIUS STEDIM BIOTECH SHS : Solid growth at Sartorius Stedim Biotech; profits..
07/18SARTORIUS STEDIM BIOTECH SA : half-yearly earnings release
07/18 SARTORIUS STEDIM BIOTECH : introduces complete range of chemistry testing servic..
06/27 SARTORIUS STEDIM BIOTECH : Partners with Nova Biomedical
06/01 SARTORIUS STEDIM BIOTECH : launches next generation BIOSTAT STR bioreactors
04/19SARTORIUS STEDIM BIOTECH SA : quaterly earnings release
04/07 SARTORIUS STEDIM BIO : ex-dividend day for annual dividend
04/04 SARTORIUS STEDIM BIOTECH SHS : Resolutions of the Annual Shareholders' Meeting o..
02/21 SARTORIUS STEDIM BIO : Resolutions by the Board of Directors
02/08 SARTORIUS STEDIM BIO : 2016 targets fully achieved; strong outlook for 2017
More news
News from SeekingAlpha
07/21 Sartorius Stedim Biotech reports 1H results
04/24 Sartorius Stedim Biotech reports Q1 results
04/03 MKS announces sale of data analytics solutions business
Financials (€)
Sales 2017 1 146 M
EBIT 2017 257 M
Net income 2017 175 M
Debt 2017 102 M
Yield 2017 0,70%
P/E ratio 2017 31,69
P/E ratio 2018 27,11
EV / Sales 2017 5,11x
EV / Sales 2018 4,68x
Capitalization 5 757 M
Chart SARTORIUS STEDIM BIOTECH
Duration : Period :
Sartorius Stedim Biotech Technical Analysis Chart | DIM | FR0013154002 | 4-Traders
Technical analysis trends SARTORIUS STEDIM BIOTECH
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Average target price 66,8 €
Spread / Average Target 7,0%
EPS Revisions
Managers
NameTitle
Joachim Kreuzburg Chairman, CEO, CFO & Head-Human Resources
Volker Niebel Executive VP-Operations & Information Technology
Oscar-Werner Reif EVP-Research & Development
Liliane de Lassus Independent Non-Executive Director
Bernard Lemaître Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
SARTORIUS STEDIM BIOTECH4.14%6 758
MEDTRONIC PLC18.76%114 960
BAXTER INTERNATIONAL37.12%33 128
C R BARD INC42.81%23 315
ZIMMER BIOMET HOLDINGS INC9.47%22 842
HOYA CORPORATION29.42%22 449